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Abstract
Background: On the borders of Thailand, Plasmodium falciparum has become resistant to nearly
all available drugs, and there is an urgent need to find new antimalarial drugs or drug combinations.
Ferroquine (SSR97193) is a new 4-aminoquinoline antimalarial active against chloroquine resistant
and sensitive P. falciparum strains in vivo and in vitro. This antimalarial organic iron complex (a
ferrocenyl group has been associated with chloroquine) is meant to use the affinity of Plasmodium
for iron to increase the probability for encountering the anti-malarial molecule.
The aim of the present study was to investigate the activity of ferroquine against P. falciparum
isolates from an area with a known high multi-drug resistance rate.
Methods: Parasite isolates were obtained from patients with acute falciparum malaria attending
the clinics of SMRU. In vitro cultures of these isolates were set-up in the SMRU-laboratory on pre-
dosed drug plates, and grown in culture for 42 hours. Parasite growth was assessed by the double-
site enzyme-linked pLDH immunodetection (DELI) assay.
Results: Sixty-five P. falciparum isolates were successfully grown in culture. The ferroquine mean
IC50 (95% CI) was 9.3 nM (95% C.I.: 8.7 – 10.0). The mean IC50 value for the principal metabolite
of ferroquin, SR97213A, was 37.0 nM (95% C.I.: 34.3 – 39.9), which is four times less active than
ferroquine. The isolates in this study were highly multi-drug resistant but ferroquine was more
active than chloroquine, quinine, mefloquine and piperaquine. Only artesunate was more active
than ferroquine. Weak but significant correlations were found between ferroquine and its principal
metabolite (r2 = 0.4288), chloroquine (r2 = 0.1107) and lumefantrine (r2 = 0.2364).
Conclusion: The results presented in this study demonstrate that the new ferroquine compound
SSR97193 has high anti-malarial activity in vitro against multi-drug resistant P. falciparum.
Background
The emergence of drug resistant malaria is a serious threat
for malarial control [1,2]. Currently, chloroquine-resist-
ant Plasmodium falciparum parasites are prevalent in most
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of the tropics, and in many areas resistance is high grade
(i.e. potentially dangerous, with early treatment failures
occurring) [1,2]. The rapid spread of chloroquine resist-
ance has forced clinicians in many regions of the world to
abandon classical therapy with chloroquine, in favour of
other drugs that are less well tolerated and, importantly,
more expensive. The situation in South-east Asia is of par-
ticular concern with increasingly frequent cases of 'multi-
drug' resistant malaria [3]. On the borders of Thailand, P.
falciparum  has become resistant to nearly all available
drugs [4,5]. These observations highlight the urgent need
to find new antimalarial drugs or drug combinations and
to develop optimal treatment protocols.
Most new drugs arise from the identification of new ther-
apeutic targets or metabolic pathways. Another approach
is to modify an existing drug to enhance its activity [6].
Ferroquine (SSR97193) is a new 4-aminoquinoline anti-
malarial active against chloroquine resistant and sensitive
P falciparum strains in vivo and in vitro [6-8] (Figure 1).
This antimalarial organic iron complex (a ferrocenyl
group has been associated with chloroquine) is meant to
use the affinity of Plasmodium  for iron to increase the
probability for encountering the anti-malarial molecule
[6-9]. The ferrocene group by itself does not have antima-
larial activity [8].
Four previous studies had investigated the activity of fer-
roquine against P. falciparum isolates from infected
patients [10-13] (Table 1). However, the drug sensitivity
of P. falciparum strains varies between different locations,
where P. falciparum isolates have different anti-malarial
resistance backgrounds.
The aim of the present study was to confirm the efficiency
of ferroquine against P. falciparum isolates from patients
treated for malaria in one of the SMRU clinics along the
Thai-Burmese border. This area has a known high multi-
drug-resistance rate, with very high resistance against
chloroquine [14].
Methods
Isolates of Plasmodium falciparum
Between November 2004 and May 2005 parasite isolates
were obtained from patients with acute falciparum
malaria attending the clinics of the Shoklo Malaria
Research Unit (SMRU). The clinics are open for both
migrants and refugees and are situated in an area of for-
ested hills on the northwestern border of Thailand. Iso-
lates were collected if the parasitaemia was at least 0.1%,
by taking 5 cc whole blood by venopunture into sterile
Vacutainer® tubes containing 0.05 ml K3 EDTA. The blood
samples were transported within 4–6 hours at room tem-
perature and then set up in continuous culture upon their
arrival in the SMRU laboratory in Mae Sot, not more than
one-hour drive from the study sites. Samples were only
provided by patients who gave written, informed consent
following written and oral explanations given in their
own language. This study was part of a series of treatment
trials approved by the Ethical Committee of the Faculty of
Tropical Medicine, Mahidol University, Bangkok, Thai-
land.
In vitro drug assay
Ferroquine (FQ) (SSR97193: 7-chloro-4-[(2-N,N-dime-
thyl-aminomethyl) ferrocenylmethylamino]quinoline),
and ferroquine metabolite (FQM) (SR97213A:
C22H22ClFeN3) (Figure 1) were obtained from Sanofi-Syn-
thelabo-Recherche, France. Chloroquine diphosphate
(CQ), quinine citrate (QN) and doxycyline hydrochloride
(DOX) were obtained from Sigma Chemicals, UK. Lume-
fantrine (LUM) was obtained from Novartis Pharmacia,
Basel, Switzerland. Sodium artesunate (AS), piperaquine
(PIP) and mefloquine (MFQ) were kindly donated by Dr.
Niklas Lindegård, Faculty of Tropical Medicine, Mahidol
University, Thailand. FQ and FQM were dissolved in
DMSO, QN, MFQ and AS in 70% ethanol, CQ and DOX
in deionised water, PIP in 100% methanol and LUM was
dissolved in a 1:1:1 (w/v) mixture of ethanol, Triton-X
(Sigma), linoleic acid (Sigma). All drugs were dissolved
initially at a concentration of 1 mg/ml, and serial dilu-
tions were made in complete RPMI medium. The solvent
in the final concentrations had no significant effect on
parasite growth when compared to culture media. All con-
centrations, including drug-free controls, were distributed
in duplicate in 96-well tissue culture plates. The drug-
plates were made in bulk and stored at -80°C until use
(for up to three months).
For each sample, plasma and buffy coat were removed
after centrifugation and the red cells washed three times in
phosphate buffered saline (PBS). The infected red blood
cells were set-up in the pre-dosed drug plates in complete
RPMI with 10% heterologous sera, at a parasitaemia of
0.1% parasitized erythrocytes and a haematocrit of 1.5%.
The plates were incubated at 37°C in the presence of 5%
Chemical structure of ferroquine (7-chloro-4-[(2-N,N-dime- thyl-aminomethyl) ferrocenylmethylamino]quinoline) and its  principal metabolite Figure 1
Chemical structure of ferroquine (7-chloro-4-[(2-N,N-dime-
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CO2, 90% N2 and 5% O2 for 42 hours. After culture the
plates were frozen down at -20°C.
The chloroquine-resistant P. falciparum laboratory clone
K1 was used for quality control of the drug-plates.
DELI
The double-site enzyme-linked pLDH immunodetection
(DELI) assay was used to assess P. falciparum antimalarial
drug susceptibility. The DELI method was performed as
described previously [15,16]. In brief, the culture plates
were thawed and frozen three times order to lyse the cells.
100 μl from each well were transferred into 96-well plates
(Nunc-Immuno™ plate, maxisorb, Nalgene Nunc Interna-
tional, Denmark) pre-coated with a capture monoclonal
antibody 17E4, which specifically recognizes the pLDH,
incubated for 1 hour at 37°C. Following washing 3× with
PBS/0.5% bovine serum albumin (BSA Fraction V)
(Roche Diagnostics, Mannheim, Germany), a second
biotinylated anti-pLDH monoclonal antibody 19G7 was
added and the plates incubated for 1 hour at 37°C. After
removal of unbound antibody by washing 3× with PBS/
0.5% BSA, the plates were incubated at room temperature
for 30 minutes with a 1:10,000 solution of streptavidin-
POD conjugate (Roche Diagnostics). After washing the
plates 3× with PBS/0.5% BSA, the plates were incubated
for up to 20 minutes at room temperature with a peroxi-
dase substrate solution, 3,3',5,5'-tetramethylbenzidine
(KPL, Maryland, USA). The reaction was stopped with 1 M
phosphoric acid and colour development was quantified
immediately using a spectrophotometer to determine the
OD at 450 nm with a reference filter at 690 nm.
Analysis of dose response curves
Dose response curves, IC50 values, and coefficients of var-
iation were calculated by fitting the data to an inhibitory
E-max pharmacokinetic model using WINNONLIN Ver
4.1 (Pharsight Corporation). To ensure data quality we
rejected all IC50  values with coefficients of variation
(Standard Error × 100)/Mean) of estimated IC50 values >
30% and those in which the pLDH production in control
wells (parasites, no drug) was < 5 times background (red
blood cells only).
Statistical analysis
Data were analysed using the program SPSS 11.0 for Win-
dows (SPSS Inc., Chicago, Illinois, USA). Prior to analysis,
in vitro drug response data were normalized by log trans-
formation. Ferroquine cross-resistance with the other
antimalarials (metabolite, chloroquine, artesunate, qui-
nine, mefloquine, lumefantrine, doxycyclin and piper-
aquine) was estimated by Pearson correlation coefficient
(r) and coefficient of determination (r2).
Results
Sixty-five  P. falciparum isolates from non-pregnant
patients were successfully grown in culture and gave inter-
pretable results for the calculation of the mean drug IC50
values as shown in Table 2. The ferroquine mean IC50 was
9.30 (95% C.I.: 8.69 – 9.96) nM, with individual values
ranging from 3.86 to 18.23 nM. The mean IC50 value for
ferroquine metabolite, the principal metabolite of ferro-
quine, was 37.00 nM (95% C.I.: 34.32 – 39.89), which is
almost 4 times less active than ferroquine. All isolates
were resistant against chloroquine using the standard cut-
off IC50 of 100 nM. The mean IC50 value for chloroquine
was 340.75 nM (95% C.I.: 304.04 – 381.89), which
makes ferroquine 36-fold more potent than chloroquine
in these isolates. A weak but significant correlation was
found between ferroquine with ferroquine metabolite (r =
0.655, r2 = 0.4288, P = 0.0001) and ferroquine with chlo-
roquine (r = 0.333, r2 = 0.1107, P = 0.009 (Table 2). Also
a significant correlation was observed between the IC50
for ferroquine and quinine. However this correlation was
not reproducible in a second set of samples. No signifi-
cant correlation between ferroquine and artesunate was
detected.
For a subset of the P. falciparum isolates (n = 22) the IC50
values for doxycycline, lumefantrine, mefloquine and
piperaquine were analysed as well (Table 3). These data
showed that ferroquine was more active than any of these
drugs in this group of isolates. Only for lumefantrine a sig-
nificant correlation with ferroquine was found (r = 0.486,
r2 = 0.2364, P = 0.025).
Table 1: Publications on the activity of ferroquine against P. falciparum isolates
Drug IC50 (Geometric mean)
Year Country Region No. of isolates Ferroquine Chloroquine Method
Pradine et al. [10] 2001 Gabon Libreville 103 10.8 nM 370 nM Isotopic microtest
Atteke et al. [12] 2003 Gabon Franceville 56 16.0 nM 141.3 nM Isotopic microtest
Bakoumba 60 27.9 nM 398.0 nM
Pradine et al. [11] 2002 Senegal 55 7.9 nM 102 mM Isotopic microtest
Chim et al. [13] 2004 Cambodia 127 30.61 nM 125.04 nM Isotopic microtestMalaria Journal 2007, 6:81 http://www.malariajournal.com/content/6/1/81
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Discussion
This study confirms that ferroquine (SSR97193) is highly
active against P. falciparum in vitro. The P. falciparum iso-
lates analysed in this study were highly multi-drug resist-
ant but ferroquine was more active than chloroquine,
quinine, mefloquine, piperaquine and doxycycline. Only
artesunate was more active than ferroquine. In addition,
ferroquine was four times more active in vitro than the
tested principal ferroquine metabolite (SR97213A). This
underlines the importance to test the biological activity of
the plasma and whole blood of treated patients or volun-
teers, as other metabolites may be active.
Weak but significant correlations between the response to
ferroquine and that to chloroquine and lumefantrine
were found. The high activity of ferroquine on chloro-
quine-resistant P. falciparum (the lowest CQ IC50 ana-
lysed is 102.4 nM) suggests either that both drugs have
different modes of action, or that ferroquine reverses chlo-
roquine resistance [12]. Chloroquine is believed to act by
concentrating in the parasite digestive vacuole and pre-
venting the conversion of toxic heme to haemozoin, lead-
ing to membrane damage and parasite death [17,18]. Biot
et. al. recently demonstrated that ferroquine, like chloro-
quine, forms complexes with haematin and is an even
stronger inhibitor of β-haematin formation than chloro-
quine [9]. Chloroquine-resistant parasites expel chloro-
quine much more rapidly from red blood cells than
chloroquine-sensitive parasites. This efflux of chloroquine
is catalyzed by a P. falciparum transmembrane protein
(PfCRT) [18]. Ferroquine may block the PfCRT through its
lipophilic properties, acting like a resistance-reversing
agent [9].
So far, no resistance of P. falciparum to ferroquine has
been found in vitro either in cultures of patient isolates or
in laboratory-adapted strains under drug pressure [18].
In Table 1, the published studies on the in vitro suscepti-
bility to ferroquine and chloroquine are summarized. The
isolates tested in the present study show comparable in
vitro  sensitivity to ferroquine to that found in Gabon
(Libreville) [10] and Senegal [11]. Isolates from Cambo-
dia have the highest IC50 values for ferroquine. However,
caution must be exerted when comparing these results
because in the present study a DELI method rather than an
isotopic assay is used. Previous reports have demonstrated
that DELI does slightly overestimate the IC50 for chloro-
quine and lumefantrine, and underestimate for artesu-
nate, compared to the isotopic microtest [14]. No data on
the direct comparison of DELI with the isotopic microtest
for ferroquine levels are available as yet.
The results presented in this study indicate that ferroquine
is active in vitro regardless of high grade multi-drug resist-
ance. Still further research is needed to elucidate the mode
Table 3: The in vitro IC50 responses of a subset of Plasmodium falciparum isolates (n = 22) to Ferroquine, Ferroquine metabolite, 
Doxycyxline, Lumefantrine, Mefloquine, and Piperaquine. Ferroquine cross-resistance with the other antimalarials was estimated by 
Pearson correlation coefficient (r), and coefficient of determination (r2).
Mean inhibitory concentration (nM)
Drug No. of isolates Geometric mean 95% confidence interval rr 2 P
Ferroquine 21 8.91 8.17 – 9.72 - - -
FQ-Metabolite 22 31.40 28.16 – 35.01 0.674 0.4542 0.001
Doxycycline 20 2719.85 2236.38 – 3307.09 -0.203 0.0411 0.391
Lumefantrine 22 11.77 10.31 – 13.44 0.486 0.2364 0.025
Mefloquine 21 144.23 125.82 – 165.33 0.296 0.0874 0.206
Piperaquine 19 49.20 37.16 – 65.11 0.017 0.0003 0.946
Table 2: The in vitro IC50 responses of the 65 isolates of Plasmodium falciparum to ferroquine, ferroquine metabolite, chloroquine, 
artesunate and quinine. Ferroquine cross-resistance with the other antimalarials was estimated by Pearson correlation coefficient (r), 
and coefficient of determination (r2)
Mean inhibitory concentration (nM)
Drug No. of isolates Geometric mean 95% confidence interval rr 2 P
Ferroquine 65 9.30 8.69 – 9.96 - - -
FQ-Metabolite 64 37.00 34.32 – 39.89 0.655 0.4288 0.0001
Chloroquine 62 340.75 304.04 – 381.89 0.333 0.1107 0.0090
Artesunate 56 4.02 3.06 – 6.28 -0.169 0.0284 0.2190
Quinine 49 1016.05 894.36 – 1154.29 0.338 0.1145 0.0200Publish with BioMed Central    and   every 
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of action of ferroquine and identify the putative molecu-
lar markers of resistance. In addition, since chloroquine
resistance is also found in Plasmodium vivax [19], the activ-
ity of ferroquine to P. vivax should be studied.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MB carried out the study and analysed the data. AJ and NK
carried out the parasite cultures and ELISA assays. MB, PS
and FN participated in the study design and contributed
to draft the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
We would like to thank all the patients and staff of the Shoklo Malaria 
Research Unit. We are also grateful to Sanofi-Aventis and Dr. Niklas Lin-
degårdh for providing the drugs used in the in vitro assays. This study 
received financial support from Sanofi-Aventis. The Shoklo Malaria 
Research Unit is part of the Wellcome Trust-Mahidol University, Oxford 
Tropical Medicine Research Programme sponsored by The Wellcome 
Trust of Great Britain.
References
1. White NJ: Antimalarial drug resistance and combination
chemotherapy.  Philos Trans R Soc Lond B Biol Sci 1999, 354:739-749.
2. Barnes KI, White NJ: Population biology and antimalarial
resistance: the transmission of antimalarial drug resistance
in Plasmodium falciparum.  Acta Trop 2005, 94:230-240.
3. World Health Organization: World malaria report 2005 Geneva; 2005. 
4. Reacher M, Campbell CC, Freeman J, Dobersteyn EB, Brandling-Ben-
net AD: Drug therapy for Plasmodium falciparum malaria
resistant to pyrimethamine-sulfadoxine (Fansidar). A study
of alternate regimens in Eastern Thailand, 1980.  Lancet 1981,
2:1066-1069.
5. White NJ: Antimalarial drug resistance: the pace quickens.  J
Antimicrob Chemother 1992, 30:571-585.
6. Delhaes L, Abessolo H, Biot C, Berry L, Delcourt P, Maciejewski L,
Brocard J, Camus D, Dive D: In vitro and in vivo antimalarial
activity of ferrochloroquine, a ferrocenyl analogue of chloro-
quine against chloroquine-resistant malaria parasites.  Parasi-
tol Res 2001, 87:239-244.
7. Biot C, Glorian G, Maciejewski L, Brocard J, Domarle O, Blampain G,
Millet P, Georges AJ, Abessolo H, Dive D, Lebibi J: Synthesis and
antimalarial activity in vitro and in vivo of a new ferrocene-
chloroquine analogue.  J Med Chem 1997, 40:3715-3718.
8. Domarle O, Blampain G, Agnaniet H, Nzadiyabi T, Lebibi J, Brocard J,
Maciejewski L, Biot C, Georges AJ, Millet P: In vitro antimalarial
activity of a new organometallic analog, ferrocene-chloro-
quine.  Antimicrob agents Chemother 1998, 42(3):540-544.
9. Biot C, Taramelli D, Forfar-Bares I, Maciejewski L, Boyce M, Nowo-
grocki G, Brocard J, Basilico N, Olliaro P, Egan TJ: Insights into the
mechansims of action of ferroquine. Relationship between
physicochemical properties and antiplasmodial activity.  Mol
Pharm 2005, 2:185-193.
10. Pradines B, Fusai T, Daries W, Laloge V, Rogier C, Millet P, Panconi
E, Kombila M, Parzy D: Derrocene-chloroquine analogues as
antimalarial agents: in vitro activity of ferrochloroquine
against 103 Gabonese isolates of Plasmodium falciparum.  J
Antimicrob Chemother 2001, 48:179-184.
11. Pradines B, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L, Fusai T,
Millet P, Panconi E, Trape JF, Parzy D: In vitro activities of ferro-
chloroquine against 55 Senegalese isolates of Plasmodium fal-
ciparum in comparison with those of standard antimalarial
drugs.  Trop Med Int Health 2002, 7:265-270.
12. Atteke C, Ndong JN, Aubouy A, Maciejewski L, Brocard J, Lebibi J,
Deloron P: In vitro susceptibility to a new antimalarial orga-
nometallic analogue, ferroquine, of Plasmodium falciparum
isolates from the Haut-Ogooue region of Gabon.  J Antimicrob
Chemother 2003, 51:1021-1024.
13. Chim P, Lim P, Sem R, Nhem S, Maciejewski L, Fandeur T: The in-
vitro antimalarial activity of ferrochloroquine measured
against Cambodian isolates of Plasmodium falciparum.  Ann
Trop Med Parasitol 2004, 98:419-424.
14. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto
P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F: Plas-
modium falciparum antimalarial drug susceptibility on the
north-western border of Thailand during five years of exten-
sive use of artesunate-mefloquine.  Trans R Soc Trop Med Hyg
2000, 94:537-544.
15. Druilhe P, Moreno A, Blanc C, Brasseur PH, Jacquier P: A colori-
metric  in vitro sensitivity assay for Plasmodium falciparum
based on a highly sensitive double-site LDH antigen capture
ELISA.  Am J Trop Med Hyg 2001, 64:233-241.
16. Brockman A, Singlam S, Phiaphun L, Looareesuwan S, White NJ, Nos-
ten F: Field evaluatiuon of a novel colorimetric method – dou-
ble-site enzym-linked lactate dehydrogenase
immunodetection assay – to determine drug susceptibilities
of Plasmodium falciparum clinical isolates from northwestern
Thailand.  Antimicrob agents Chemother 2004, 48:1426-1429.
17. Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley
RG: An assesment of drug-haematin binding as a mechanism
for inhibition of haematin polymerisation by quinoline anti-
malarials.  Biochem Pharmacol 1998, 55:727-736.
18. Daher W, Biot C, Fandeur T, Jouin H, Pelinski L, Viscogliosi E, Fraisse
L, Pradines B, Brocard J, Khalife J, Dive D: Assessment of Plasmo-
dium falciparum resistance to ferroquine (SSR97193) in field
isolates and in W2 strain under pressure.  Malaria Journal 2006,
5:11.
19. Maguire JD, Krisin , Marwoto H, Richie TL, Fryauff DJ, Baird JK:
Mefloquine is highly efficacious against chloroquine-resistant
Plasmoidum vivax malaria and Plasmodium falciparum malaria
in Papua, Indonesia.  Clin Infect Dis 2006, 42:1073-1074.